outperform price
thought
 play
take finish tidi organ revenue beat
expect buy-sid solid opex
manag thought impress revenue
expect coupl notabl item commentari
order rate revenue growth rev
think debat around st guidanc
appropri multipl guidanc seem
prudent conserv ceo mike mcmullen state
macro hasnt worsen take cautiou approach
similar mtd commentari note china food
stabil sequenti dd declin
pmi bottom set stage potenti revenu upsid
margin front think initi
taken expand digit footprint provid structur
opportun
support b/ deploy toward potenti sourc
upsid tax rate opportun see stabl doubl
digit ep grower kind visibl potenti revenue
acceler expect trade premium head
elect year reiter outperform rate
rais pt equat price-to-earnings higher
year number
medium
guid color market color c/c color
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
acg hsd broad base dgg hsd ldd nasd ramp lsag flat
america continu hsd europ lsd apac low msd china low msd
expect growth continu
china food dd declin flat last quarter /q
lunar new yr pt revenue impact
frederick site ramp bake
pharma driven larg molecul cross lab esp impress comp
surprisingli dd
led biolog nasd small molecul
 driven solid fund impact season
environment forens driven balanc lsag acg comp
food due china
repres sequenti stabil
dx driven patholog highlight
america expect driven pharma dx env
europ slightli expect
apac ex-china lsd
china lsd due weak food food pt hw
recogn revenu frederick co biopharma site first time
omx driven solid oper leverag expens manag
management acknowledg guid could prove conserv
digit order drive fundament chang cost structur manag
although instrument recoveri like management assum flat condit guid
leverag target remain ceil net leverag ye
management increasingli confid deliv larg acquisit
privat lab track well china
cite issu fill order nasd capac ramp
consist larg molecul growth repres north pharma
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin novemb
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
